<SEC-DOCUMENT>0001193125-21-230075.txt : 20210730
<SEC-HEADER>0001193125-21-230075.hdr.sgml : 20210730
<ACCEPTANCE-DATETIME>20210730073159
ACCESSION NUMBER:		0001193125-21-230075
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210730
FILED AS OF DATE:		20210730
DATE AS OF CHANGE:		20210730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		211130043

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d277633d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of July 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-39173</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 802,
West Tower, OmniVision, 88 Shangke Road, Pudong District </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shanghai, 201210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>People&#146;s Republic of China </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">I-MAB</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jielun Zhu</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jielun Zhu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director and Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: July&nbsp;30, 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit Index </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit 99.1&#151;Press Release </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d277633dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g277633ex99_1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Announces IND Acceptance for Phase 2 Clinical Trial of
Efineptakin Alfa in Combination with <FONT STYLE="white-space:nowrap">PD-1</FONT> Therapy in China </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- Efineptakin alfa in
combination with pembrolizumab induced 27.8% ORR in metastatic TNBC patients in a phase 1b/2 trial in South Korea </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- Efineptakin alfa
in patients with GBM showed a 83.3% survival ratio over one year in a phase 1 trial in the U.S. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SHANGHAI, China and GAITHERSBURG, MD.
</B><B>&#150; July</B><B></B><B>&nbsp;22, 2021 &#150;</B> <FONT STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and
commercialization of novel biologics, today announced that an IND application for the initiation of a phase 2 clinical trial of efineptakin alfa (also known as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">TJ107/GX-I7/NT-I7)</FONT></FONT> in combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody in patients with advanced solid
tumors, including triple-negative breast cancer (TNBC) and head and neck cancers (HNC), has been accepted by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efineptakin alfa is the world&#146;s first and only long-acting recombinant human <FONT STYLE="white-space:nowrap">interleukin-7</FONT> <FONT
STYLE="white-space:nowrap">(&#147;rhIL-7&#148;)</FONT> being developed as a T lymphocyte-booster for cancer-related immunotherapy. Efineptakin alfa is expected to show a therapeutic effect as a combination therapy with immune checkpoint inhibitors
due to its inherent properties to increase <FONT STYLE="white-space:nowrap">T-cells</FONT> that are critical for tumor suppression. Its <FONT STYLE="white-space:nowrap">T-cell</FONT> properties comes with unique selectivity that only stimulates
tumor-fighting lymphocytes and spares tumor-protecting Treg cells, differentiating it from other cytokines such as human <FONT STYLE="white-space:nowrap">IL-2.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The IND submission leverages accumulative clinical data from multiple previous studies of efineptakin alfa as monotherapy and in combination with checkpoint
inhibitors in the treatment of advanced solid tumors, conducted by <FONT STYLE="white-space:nowrap">I-Mab</FONT> in China and Genexine and NeoImmuneTech in South Korea and the U.S., respectively. Data from the phase 1b/2 <U><FONT
STYLE="white-space:nowrap">Keynote-899</FONT></U> study, presented at SITC 2020, have shown that simultaneuous treatment of efineptakin alfa at 1200&micro;g/kg with pembrolizumab (Keytruda<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>)
induced 27.8% ORR in patients with metastatic TNBC. According to the data from <FONT STYLE="white-space:nowrap">NIT-110</FONT> dose escalation presented at ASCO 2021, the combination treatment was safe and well-tolerated in the study. In addition,
interim results from the phase 1 trial (<U>NCT03687957</U>) in newly diagnosed patients with high-grade gliomas that have undergone chemoradiotherapy showed that absolute lymphocyte count (ALC) increased by 1.3 &#150; 4.1 fold at week 4 in a
dose-dependent manner and lasted up to 12 weeks after injection, with a one-year survival rate of 83.3% being observed so far.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> Furthermore, a phase 1b trial (<U>NCT04001075</U>) in China is about
to complete to facilitate the further development of efineptakin alfa. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Data can be viewed in NeoImmuneTech&#146;s poster presentation at 2021 ASCO Annual Meeting at the following
link: <U>http://neoimmunetech.com/_down.html?upload=%2Fupload_rb&amp;fname=AX_7356756659.pdf&amp;orifname=nit_ir%20presentation_asco2021_e.pdf</U> </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g277633ex99_1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Current clinical data suggest that efineptakin alfa has the great potential to revolutionize the
treatment in particularly <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> cancers,&#148; said Dr.&nbsp;Joan Shen, CEO of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> &#147;We have already
initiated a phase 2 trial in lymphopenic patients with newly-diagnosed glioblastoma multiforme earlier this year. With these additional studies, we hope to fast-track the clinical development of efineptakin alfa in China and bring this potentially
very valuable treatment to a large population of cancer patients.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Efineptakin alfa </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efineptakin alfa, also known as <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">TJ107/GX-I7/NT-I7,</FONT></FONT> is the world&#146;s first and only long-acting recombinant human <FONT STYLE="white-space:nowrap">interleukin-7</FONT>
<FONT STYLE="white-space:nowrap">(rhIL-7),</FONT> known to boost T lymphocytes by increasing their number and functions.&nbsp;It emerged&nbsp;from&nbsp;Genexine&#146;s proprietary hyFc<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
platform for the discovering of long-acting biologics. <FONT STYLE="white-space:nowrap">I-Mab</FONT> has acquired exclusive rights from Genexine to develop and commercialize efineptakin alfa in Greater&nbsp;China. Efineptakin alfa&nbsp;may have
utility in cancer treatment-related lymphopenia (low blood lymphocyte levels), a common condition that occurs in cancer patients who have received chemotherapy or radiation therapy, for which there is no approved treatment. Efineptakin alfa
has&nbsp;also&nbsp;been shown to synergize with a <FONT STYLE="white-space:nowrap">PD-1</FONT> antibody in various tumor animal models potentially through increased <FONT STYLE="white-space:nowrap">T-lymphocyte</FONT> activation and proliferation.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon,
commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company&#146;s mission is to bring transformational medicines to patients around the world through innovation. <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> innovative pipeline of more than 10 clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage drug candidates is driven by the Company&#146;s
<FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(Proof-of-Concept)</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT>
development strategies through internal R&amp;D and global partnerships. The Company is on track to transition from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&amp;D capabilities,
world-class GMP manufacturing facilities and commercial capability. <FONT STYLE="white-space:nowrap">I-Mab</FONT> has offices in Beijing, Shanghai, Hangzhou, Hong Kong and Maryland, United States. For more information, please visit <U><FONT
STYLE="white-space:nowrap">http://ir.i-mabbiopharma.com</FONT></U> and follow <FONT STYLE="white-space:nowrap">I-Mab</FONT> on <U>LinkedIn</U>, <U>Twitter</U> and <U>WeChat</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g277633ex99_1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities
laws, including statements regarding data from the efineptakin alfa phase 1/2 trial, the potential implications of clinical data for patients, and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> advancement of, and anticipated clinical
development, regulatory milestones and commercialization of efineptakin alfa. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or NDA/BLA approval; the content and timing
of decisions made by the relevant regulatory authorities regarding regulatory approval of <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> drug candidates; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to achieve commercial
success for its drug candidates, if approved; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain and maintain protection of intellectual property for its technology and drugs; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT>
reliance on third parties to conduct drug development, manufacturing and other services; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> limited operating history and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain
additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s clinical development, commercial
and other operations, as well as those risks more fully discussed in the &#147;Risk Factors&#148; section in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> most recent annual report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> as well
as discussions of potential risks, uncertainties, and other important factors in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on
information currently available to <FONT STYLE="white-space:nowrap">I-Mab,</FONT> and <FONT STYLE="white-space:nowrap">I-Mab</FONT> undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Contacts </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jielun Zhu</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gigi Feng</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Communications Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U><FONT STYLE="white-space:nowrap">jielun.zhu@i-mabbiopharma.com</FONT></U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U><FONT STYLE="white-space:nowrap">gigi.feng@i-mabbiopharma.com</FONT></U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">+86 21 6057 8000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">+86 21 6057 8000</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Inquiries </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>The Piacente Group, Inc.</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Emilie Wu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <U>emilie@thepiacentegroup.com</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Office line: +86 21 6039 8363</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g277633ex99_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g277633ex99_1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MAKQCJFG20RG3B"IN&0JA*G*G/3H3^=&(J0E34F[,5",J=1QZ&G\0O#\OBAK
MV5U"@MA(&WJYSNVXQM4^AKEHXVC1O>[]$V:5Z;J6L9WB#P5X>B\-S/IEA.=1
M51LVNX)/?ASR/8#-71Q\9SLY67FK&=2A!0]U:F[\,M/U+3_"VS4$>(/,SQ12
M##*I [=N0QQ[U>(E&4[Q-<-&48:G:5SG2<E\3'9/AYJQ7J1&OX&10?YUT89?
MO4<V*=J,CPS1W-M.L@&1C!'M7O1T/FZBNK'J7@K2(M5U W,R[K>W ;&.&8]
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.. % !0 4 % !0 4 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
